The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Interest in Shares

19 Oct 2017 09:20

RNS Number : 0668U
Hutchison China Meditech Limited
19 October 2017
 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Hutchison China MediTech Limited

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: iii

Slater Investments Limited

4. Full name of shareholder(s) (if different from 3.):iv

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

18 October 2017

6. Date on which issuer notified:

18 October 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 3%

      
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

KYG4672N1016

1,824,926

1,824,926

232,538

232,538

 1,581,388

0.38%

2.60%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,813,926

2.98%

                
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

14. Contact name:

Ralph Baber

15. Contact telephone number:

+ 44 20 7220 9460

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLMLBPTMBBBMTR
Date   Source Headline
29th Mar 20168:00 amRNSDirector/PDMR Shareholding
23rd Mar 201610:34 amRNSHolding(s) in Company
22nd Mar 20162:00 pmRNSClosing of U.S. Public Offering of ADSs
21st Mar 20168:54 amRNSDirector/PDMR Shareholding
21st Mar 20167:00 amRNSSulfatinib Phase III registration study
18th Mar 20164:18 pmRNSFinal Prospectus
17th Mar 20167:00 amRNSPricing of U.S. Public Offering of ADSs
15th Mar 20167:00 amRNS2015 Annual Report and Notice of AGM
7th Mar 20167:59 amRNSFifth Filing of Form F-1 Registration Statement
4th Mar 20166:12 pmRNSLaunch of Potential U.S. Public Offering of ADSs
4th Mar 20165:54 pmRNSFifth Filing of Form F-1 Registration Statement
2nd Mar 20167:00 amRNSSulfatinib Phase II initation in thyroid cancer
1st Mar 20164:29 pmRNSFourth Filing of Form F-1 Registration Statement
1st Mar 20167:00 amRNSFinal Results
11th Feb 20165:39 pmRNSPublic Filing of Form F-1 Registration Statement
29th Jan 20168:03 amRNSNotice of Results
15th Jan 20167:02 amRNSChi-Med initiates HMPL-523 Phase I clinical trial
29th Dec 20157:43 amRNSBlocklisting Six Monthly Return
18th Dec 20157:00 amRNSInitiation sulfatinib Phase III registration study
9th Dec 20157:00 amRNSUS$105 m Shanghai land compensation agreement
8th Dec 20157:00 amRNSInitiation of fruquintinib Phase 3 trial in NSCLC
13th Nov 20152:50 pmRNSSecond Public Filing of Registration Statement
10th Nov 20151:13 pmRNSResults of Extraordinary General Meeting
9th Nov 20157:59 amRNSDirector/PDMR Shareholding
6th Nov 20157:00 amRNSChi-Med initiates sulfatinib U.S. clinical trials
30th Oct 20157:00 amRNSClinical results presented
30th Oct 20157:00 amRNSTotal Voting Rights
30th Oct 20157:00 amRNSCompletion of Phase I clinical trial of HMPL 523
20th Oct 20152:40 pmRNSDirector's Share Dealing
19th Oct 20157:00 amRNSAwards under Long Term Incentive Plan
16th Oct 201512:17 pmRNSShareholders' Circular and Notice of EGM
16th Oct 201512:15 pmRNSFiling of Registration Statement on Form F1
16th Oct 201512:03 pmRNSChi-Med files Nasdaq Registration Statement
13th Oct 20157:00 amRNSEnrolment complete in Savolitinib Phase II trial
12th Oct 20152:09 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSPresentation at 2015 European Cancer Congress
2nd Sep 201511:57 amRNSTrial of fruquintinib achieves primary endpoint
19th Aug 201512:14 pmRNSTermination of R&D agreement with Janssen
28th Jul 20157:00 amRNSInterim Results
23rd Jul 20151:05 pmRNSNotification of major interest in shares
23rd Jul 20151:01 pmRNSNotification of major interest in shares
23rd Jul 20159:01 amRNSMitsui exchanges shares in Hutchison MediPharma
17th Jul 20157:00 amRNSInvention patent granted for SXBXP
6th Jul 20157:00 amRNSNotice of Announcement of 2015 Interim Results
29th Jun 20157:00 amRNSBlocklisting Six Monthly Return
1st Jun 20157:00 amRNSSavolitinib preliminary Phase Ib data presented
13th May 20157:00 amRNSFruquintinib results trigger payments from Lilly
30th Apr 20157:00 amRNSTotal Voting Rights
24th Apr 201512:40 pmRNSResult of AGM
22nd Apr 201511:23 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.